IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v23y2005i10p1007-1020.html
   My bibliography  Save this article

The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden

Author

Listed:
  • Peter Hertzman

Abstract

Objective: To calculate the cost effectiveness (from the Swedish healthcare perspective) of orlistat plus diet for an obese and overweight population in a 1-year weight-management responder programme versus a 1-year weight-management programme based on diet only. As a reference, orlistat plus diet and diet only were also compared with a no-diet alternative. Method: Costs and effectiveness were calculated in a decision-tree model by means of Monte Carlo simulation. Efficacy was derived from a pooled analysis of the orlistat clinical trial programme. Acquisition costs for orlistat (€, 2003 prices), healthcare costs for visits to doctors and dieticians related to weight management, and costs related to the difference in diabetes mellitus incidence between treatment arms were included in the analysis. The health benefit of temporary weight loss was measured in the number of quality-adjusted life-years (QALYs) gained. Results: The number of responding (those with >5% weight loss) patients at month 3 was almost twice as high with orlistat compared with diet only: 48.9% versus 26.3%. Responding orlistat patients had a weight loss of 15.5% at month 12 compared with 7.9% for all patients on diet only. The incremental cost-effectiveness ratio (ICER) per QALY gained versus diet only was estimated to be €13 125 for the average patient starting on orlistat. When orlistat was compared with no diet, the cost effectiveness was improved. However, comparing diet only with no diet gave a slightly higher ICER, indicating that orlistat had an extended dominance over the diet-only alternative. Conclusion: Our estimates indicated that orlistat in a 12-month dietary responder programme increased the number of QALYs and reduced the cumulative incidence of diabetes compared with diet only. Patients starting on orlistat in addition to a dietary programme achieved an ICER that was similar to many other well accepted healthcare treatment programmes. In order to improve the precision of our calculations, we need to confirm the key assumptions regarding temporary weight loss and utility gains, and the relationship between temporary weight loss and diabetes, as well as other co-morbidities, and to have better knowledge of the long-term impact of weight-management programmes in clinical practice, such as changes in weight-controlling behaviours and sustainability of weight loss. Copyright Adis Data Information BV 2005

Suggested Citation

  • Peter Hertzman, 2005. "The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden," PharmacoEconomics, Springer, vol. 23(10), pages 1007-1020, October.
    • Handle: RePEc:spr:pharme:v:23:y:2005:i:10:p:1007-1020
    DOI: 10.2165/00019053-200523100-00004
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200523100-00004
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200523100-00004?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. George W. Torrance & David Feeny & William Furlong, 2001. "Visual Analog Scales," Medical Decision Making, , vol. 21(4), pages 329-334, August.
    2. Torrance, George W., 1976. "Social preferences for health states: An empirical evaluation of three measurement techniques," Socio-Economic Planning Sciences, Elsevier, vol. 10(3), pages 129-136.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. J Lennert Veerman & Jan J Barendregt & Megan Forster & Theo Vos, 2011. "Cost-Effectiveness of Pharmacotherapy to Reduce Obesity," PLOS ONE, Public Library of Science, vol. 6(10), pages 1-8, October.
    2. Ulla Griffiths & Benedict Anigbogu & Kiran Nanchahal, 2012. "Economic evaluations of adult weight management interventions," Applied Health Economics and Health Policy, Springer, vol. 10(3), pages 145-162, May.
    3. Ulla K. Griffiths & Benedict Anigbogu & Kiran Nanchahal, 2012. "Economic evaluations of adult weight management interventions," Applied Health Economics and Health Policy, Springer, vol. 10(3), pages 145-162, May.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Marie-Josée Dion & Pierre Tousignant & Jean Bourbeau & Dick Menzies & Kevin Schwartzman, 2002. "Measurement of Health Preferences among Patients with Tuberculous Infection and Disease," Medical Decision Making, , vol. 22(1_suppl), pages 102-114, September.
    2. Paul F. M. Krabbe & Elly A. Stolk & Nancy J. Devlin & Feng Xie & Elise H. Quik & A. Simon Pickard, 2017. "Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(8), pages 967-977, November.
    3. Peter Franks & Erica I. Lubetkin & Joy Melnikow, 2007. "Do personal and societal preferences differ by socio‐demographic group?," Health Economics, John Wiley & Sons, Ltd., vol. 16(3), pages 319-325, March.
    4. John Vernon & Robert Goldberg & Joseph Golec, 2009. "Economic Evaluation and Cost-Effectiveness Thresholds," PharmacoEconomics, Springer, vol. 27(10), pages 797-806, October.
    5. Hilary A. Llewellyn-Thomas & J. Ivan Williams & Linda Levy & C.D. Naylor, 1996. "Using a Trade-off Technique to Assess Patients' Treatment Preferences for Benign Prostatic Hyperplasia," Medical Decision Making, , vol. 16(3), pages 262-272, August.
    6. Peter Wahlqvist & Gordon Guyatt & David Armstrong & Alessio Degl’Innocenti & Diane Heels-Ansdell & Samer El-Dika & Ingela Wiklund & Carlo Fallone & Lisa Tanser & Sander Zanten & Peggy Austin & Alan Ba, 2007. "The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD)," PharmacoEconomics, Springer, vol. 25(5), pages 385-396, May.
    7. Robert J. Brent, 2012. "The Effects Of Hiv Medications On The Quality Of Life Of Older Adults In New York City," Health Economics, John Wiley & Sons, Ltd., vol. 21(8), pages 967-976, August.
    8. Heather J. Sutherland & Hilary Llewellyn-Thomas & Norman F. Boyd & James E. Till, 1982. "Attitudes Toward Quality of Survival," Medical Decision Making, , vol. 2(3), pages 299-309, August.
    9. Milton C. Weinstein, 1981. "Economic Assessments of Medical Practices and Technologies," Medical Decision Making, , vol. 1(4), pages 309-330, December.
    10. Benjamin Matthew Craig & Kim Rand & John D. Hartman, 2022. "Preference Paths and Their Kaizen Tasks for Small Samples," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 15(2), pages 187-196, March.
    11. Peter A. Ubel & George Loewenstein, 2008. "Pain and Suffering Awards: They Shouldn't Be (Just) about Pain and Suffering," The Journal of Legal Studies, University of Chicago Press, vol. 37(S2), pages 195-216, June.
    12. Paul Dolan & Claire Gudex, 1995. "Time preference, duration and health state valuations," Health Economics, John Wiley & Sons, Ltd., vol. 4(4), pages 289-299, July.
    13. George W. Torrance & David Feeny & William Furlong, 2001. "Visual Analog Scales," Medical Decision Making, , vol. 21(4), pages 329-334, August.
    14. Peter A. Ubel & George Loewenstein & Dennis Scanlon & Mark Kamlet, 1996. "Individual Utilities Are Inconsistent with Rationing Choices," Medical Decision Making, , vol. 16(2), pages 108-116, June.
    15. Yuxuan Gu & Hao Zhang & Shahmir H. Ali & Minzhuo Huang & Jingming Wei & Shuyan Gu & Xuemei Zhen & Xiaoqian Hu & Xueshan Sun & Hengjin Dong, 2019. "Social Determinants of Health-Related Quality of Life among Residents in Zhejiang and Qinghai, China," IJERPH, MDPI, vol. 16(8), pages 1-14, April.
    16. Marisa Santos & Monica A. C. T. Cintra & Andrea L. Monteiro & Braulio Santos & Fernando Gusmão-filho & Mônica Viegas Andrade & Kenya Noronha & Luciane N. Cruz & Suzi Camey & Bernardo Tura & Paul Kin, 2016. "Brazilian Valuation of EQ-5D-3L Health States," Medical Decision Making, , vol. 36(2), pages 253-263, February.
    17. Marieke Krol & Elly Stolk & Werner Brouwer, 2014. "Predicting productivity based on EQ-5D: an explorative study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(5), pages 465-475, June.
    18. Paul F M Krabbe, 2013. "A Generalized Measurement Model to Quantify Health: The Multi-Attribute Preference Response Model," PLOS ONE, Public Library of Science, vol. 8(11), pages 1-12, November.
    19. Eric B. Bass & Earl P. Steinberg & Henry A. Pitt & Robert I. Griffiths & Keith D. Lillemoe & George P. Saba & Christina Johns, 1994. "Comparison of the Rating Scale and the Standard Gamble in Measuring Patient Preferences for Outcomes of Gallstone Disease," Medical Decision Making, , vol. 14(4), pages 307-314, October.
    20. Lena Lundberg & Magnus Johannesson & Dag G.L. Isacson & Lars Borgquist, 1999. "The Relationship between Health-state Utilities and the SF-12 in a General Population," Medical Decision Making, , vol. 19(2), pages 128-140, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:23:y:2005:i:10:p:1007-1020. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.